

Osamu Tetsu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8052711/publications.pdf>

Version: 2024-02-01

28
papers

5,402
citations

516681

16
h-index

526264

27
g-index

28
all docs

28
docs citations

28
times ranked

7528
citing authors

#	ARTICLE	IF	CITATIONS
1	β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. <i>Nature</i> , 1999, 398, 422-426.	27.8	3,405
2	Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome. <i>Science</i> , 2006, 311, 1287-1290.	12.6	505
3	Proliferation of cancer cells despite CDK2 inhibition. <i>Cancer Cell</i> , 2003, 3, 233-245.	16.8	470
4	A Critical Role for FBXW8 and MAPK in Cyclin D1 Degradation and Cancer Cell Proliferation. <i>PLoS ONE</i> , 2006, 1, e128.	2.5	177
5	The Role of mel-18, a Mammalian Polycomb Group Gene, during IL-7-Dependent Proliferation of Lymphocyte Precursors. <i>Immunity</i> , 1997, 7, 135-146.	14.3	112
6	Cancer Targets in the Ras Pathway. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2005, 70, 461-467.	1.1	95
7	Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. <i>Oncotarget</i> , 2015, 6, 4357-4368.	1.8	88
8	Genetic Profiling Reveals Cross-Contamination and Misidentification of 6 Adenoid Cystic Carcinoma Cell Lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2. <i>PLoS ONE</i> , 2009, 4, e6040.	2.5	87
9	EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E3855-63.	7.1	84
10	mel-18 Negatively Regulates Cell Cycle Progression upon B Cell Antigen Receptor Stimulation through a Cascade Leading to c-myc/cdc25. <i>Immunity</i> , 1998, 9, 439-448.	14.3	62
11	Drug Resistance to EGFR Inhibitors in Lung Cancer. <i>Chemotherapy</i> , 2016, 61, 223-235.	1.6	57
12	Mutations in the c-Kit Gene Disrupt Mitogen-Activated Protein Kinase Signaling during Tumor Development in Adenoid Cystic Carcinoma of the Salivary Glands. <i>Neoplasia</i> , 2010, 12, 708-717.	5.3	39
13	Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. <i>Human Molecular Genetics</i> , 2007, 17, 419-430.	2.9	30
14	ETS-targeted therapy: can it substitute for MEK inhibitors?. <i>Clinical and Translational Medicine</i> , 2017, 6, 16.	4.0	30
15	AKT inactivation causes persistent drug tolerance to EGFR inhibitors. <i>Pharmacological Research</i> , 2015, 102, 132-137.	7.1	29
16	TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma. <i>Laryngoscope</i> , 2014, 124, E267-73.	2.0	26
17	Fatty Acid Binding Protein 7 Is a Molecular Marker in Adenoid Cystic Carcinoma of the Salivary Glands: Implications for Clinical Significance. <i>Translational Oncology</i> , 2014, 7, 780-787.	3.7	17
18	A case of spontaneous intramural hematoma of the esophagus. <i>Gastroenterologia Japonica</i> , 1993, 28, 81-87.	0.3	16

#	ARTICLE	IF	CITATIONS
19	Short Communication Mammalian Polycomb group genes are categorized as a new type of early response gene induced by B-cell receptor cross-linking. <i>Molecular Immunology</i> , 1998, 35, 559-563.	2.2	15
20	Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer. <i>Oncology Reports</i> , 2013, 30, 584-588.	2.6	14
21	c-Kit Expression is Rate-Limiting for Stem Cell Factor-Mediated Disease Progression in Adenoid Cystic Carcinoma of the Salivary Glands. <i>Translational Oncology</i> , 2014, 7, 537-545.	3.7	13
22	Method for Screening Ecdysone-Inducible Stable Cell Lines. <i>BioTechniques</i> , 2001, 31, 414-418.	1.8	9
23	Establishment and characterization of an oral tongue squamous cell carcinoma cell line from a never-smoking patient. <i>Oral Oncology</i> , 2017, 69, 1-10.	1.5	8
24	Cloning and characterization of two transcripts generated from the mel-13 gene positioned adjacent to the mammalian Polycomb group-related gene mel-18. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1996, 1305, 109-112.	2.4	5
25	ETS1 inactivation causes innate drug resistance to EGFR inhibitors. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1078924.	0.7	5
26	Resistance to EGFR-targeted therapy by Ets-1 inactivation. <i>Cell Cycle</i> , 2015, 14, 3211-3212.	2.6	3
27	CANCER THERAPY BASED ON THE Ras PATHWAY. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2005, 70, 1-1.	1.1	1
28	A CASE OF PRIMARY OMENTAL LEIOMYOSARCOMA. <i>The Journal of the Japanese Practical Surgeon Society</i> , 1993, 54, 1648-1652.	0.0	0